KalVista Pharmaceuticals Provides Operational Update and Fiscal Year 2025 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/26/2026
- Wall Street ends higher as investors buy AI stocks; Microsoft rallies
- Stock action shows confidence in central banks: BofA’s Hartnett
- Oil prices slide about 2% as US, Iran explore path out of war
- Why stocks held up despite rising yields and $100 oil? These 2 words explain it
- Barclays asks if equity markets are nearing the boiling point
- White House blocks CNN from Air Force One trip, Washington Post reports
- Merck and Daiichi Sankyo withdraw lung cancer drug application
- Exclusive-SK Hynix's Solidigm weighs IPO that could value the unit at up to $150 billion, sources say
- Fox Factory sells Marucci Sports for $225M, cuts debt
- Wall Street ends higher as investors buy AI stocks; Microsoft rallies
Leerink Partners Reiterates Outperform Rating on Kalvista Pharmaceuticals Inc (KALV)
July 10, 2025 10:29 AM EDTLeerink Partners analyst Joseph Schwartz reiterated an Outperform rating and $20.00 price target on Kalvista Pharmaceuticals Inc (NASDAQ: KALV).
The analyst comments "We are updating our model following the disclosure of KALV's F4Q25 financial results and corporate update; the US launch for Ekterly is underway, while additional regulatory reviews are under review. As disclosed earlier this week (here), the FDA approved Ekterly (sebetralstat) as the first and only on-demand treatment for hereditary angioedema (HAE) attacks. Ekterly received... More
